AbbVie After Purchase Apogee? Is It a Buy Now for Investors
AbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
Timing matters when it comes to retirement planning. Learn when you should start planning to maximize your savings and ensure a secure future.
26,056 articlesAbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
SpaceX sits on a colossal cash hoard, but does $100 billion guarantee long-term growth? This guide breaks down what t...
A high-profile insider move by Pinterest’s leadership drew attention from investors. This deep dive explains what the...
Ford is plotting a bold move with ford's next generation electric—a scalable, low-cost EV platform designed to suppor...
What if SpaceX and xAI merged to run data centers in orbit? This article breaks down how orbital compute could work, ...
Block, the fintech and crypto payments company, is pursuing a major restructuring that could cost up to $500 million ...
As 2025 unfolds, investors weigh the promise and pitfalls of ADMA Biologics. This guide breaks down earnings drivers,...
Alphabet’s investment arm quietly backs high-growth ventures. This deep dive explains why Alphabet owns million share...
As March unfolds, the stock market today, march narrative centers on margins, capex trends, and AI-driven demand. Thi...
Sandisk has surged as AI infrastructure gains grab headlines. But can the rally last? This article lays out 3-year sc...
Poet Technologies stock plummeted today as shares fell in a broad tech rotation. This deep dive explains the main dri...
As earnings season arrives, smart investors are drilling into Transcat's 2026 earnings outlook. This guide breaks dow...